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Do mast cells help to induce angiogenesis in B-cell
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Summary Morphological and morphometric data showing a higher number of mast cells (MCs) in the stroma of B-cell non-Hodgkin's
lymphomas (B-NHL) than in benign lymphadenopathies are presented in support of the suggestion that angiogenesis during the progression
of B-NHL may be partly mediated by angiogenic factors in their secretory granules.
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Many data suggest that the density of mast cells (MCs) is highly
correlated with the extent ofboth normal and pathological angio-
genesis, such as that in chronic inflammatory diseases and tumours
(for review see Meininger and Zetter, 1992; Norrby and Woolley,
1993). In experimentally induced tumours too, MCs accumulate
close to the tumour cells before the onset ofangiogenesis (Kessler
et al, 1976), and in tumours induced in MC-deficient mice both the
reduced angiogenesis and the ability to produce metastasis have
been shown (Starkey et al, 1988; Dethlefsen et al, 1994). On the
otherhand, angiogenesis is fundamental for tumourprogression in
the form of growth, invasion and metastasis (Folkman, 1995).
Microvessels promote growth because they convey nutrients and
oxygen and remove catabolites, whereas endothelial cells secrete
paracrine growth factors for tumour cells (Hamada et al, 1992).
They facilitate invasion because endothelial cells at their tips
secrete several extracellular matrix-degrading enzymes, which
allow the tumour to spread into and through the adjacent matrix
(Mignatti and Rifkin, 1993). They permit metastasis because the
expanding endothelial surface offers tumour cells more opportuni-
ties to enter the circulation (Aznavoorian et al, 1993).
We have shown that angiogenesis is more intense in the stroma
of B-cell non-Hodgkin's lymphomas (B-NHLs) than that of
benign lymphadenopathies, and that microvessel density increases
in function with tumour progression, as defined by its increasing
malignancy grades (Ribatti et al, 1996). In this study, we correlate
the extent of angiogenesis with the number of MCs in benign
lymphadenopathies and B-NHL.
MATERIALS AND METHODS
Tissues
Representative samples of 74 B-NHL nodes and 12 benign
lymphadenopathies obtained with informed consent before therapy
were studied (Table 1). B-NHLs were classified according to the
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Working Formulation (WF) malignancy grades (1989), entailing
distinct steps of progression because of large increments in tumour
cell growthrate (S-fraction) intheintermediate andhighgrade(Wain
et al, 1987), or with transition from the low- to the intermediate- and
high-grade (Joensuu et al, 1990). Lymphadenopathies were nine
reactive and three atypical lymphoid hyperplasias. Reactive forms
displayed either follicular hyperplasia (lymphadenitides, rheumatoid
lymphadenopathies) or histiocyte hyperplasia (those draining carci-
nomas). Atypical forms displayed follicular hyperplasia.
Each sample was divided into two parts immediately after
surgical removal: one part was formalin fixed and paraffin
embedded for histopathology and immunohistochemistry; the
second was processed for electron microscopy.
Immunohistochemistry
A three-layer biotin-avidin-peroxidase system was used, as
described previously (Ribatti et al, 1996). Briefly, 8-jm sections
were deparaffinized by the xylene-ethanol sequence, depleted of
their endogenous peroxidase by 0.3% hydrogen peroxide/0.1%
sodium azide, treated with 0.1% trypsin (Sigma Chemical, St
Louis, MO, USA) and sequentially incubated with (a) murine
monoclonal antibodies (MAbs) against the endothelial cell marker
factor VIII (MAb M616, Dako Glostrup, Denmark) and various B
cell- and T cell-specific markers for typing the lymphoma lineage
and for exclusion of malignancy in atypical hyperplasias, as
described previously (Vacca et al, 1994); (b) biotin-labelled
horse anti-mouse Ig (Vector, Burlingame, CA, USA); and (c)
streptavidin-peroxidase conjugate (Dako). Sections were then
red-stained with a 3-amino-9-ethylcarbazole (Sigma Chemical)
solution, counterstained with Gill's haematoxylin no. 2
(Polysciences, Warrington, PA, USA), and mounted in buffered
glycerin. In negative controls, the MAbs were replaced by an
indifferent murine monoclonal IgG1 (Vacca et al, 1994).
Microvessel counts
These were simultaneously assessed without knowledge of the
final pathological diagnosis by two investigators with a double-
headed light microscope (Leitz Dialux 20, Leitz, Wetzlar,
Germany). Four-six 200x fields covering almost the whole of
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Table 1 Clinical and histopathological features of the patients
Lymphomas (all B-cell)
Low gradea
Average age; males/females
Small lymphocytic
Follicular, small cleaved cell
Follicular, mixed
Stage l-11/111-IV; A/B statusb
Intermediate grade
Average age; males/females
Follicular, large cell
Diffuse, small cleaved cell
Diffuse, mixed
Diffuse, large cell
Stage l-11/111-IV; A/B status
High grade
Average age; males/females
Large cell, immunoblastic
Lymphoblastic
Burkitt's (small non-cleaved cell)
Stage l-11/111-IV; A/B status
Lymphadenopathies
Average age; males/females
Reactive lymphoid hyperplasias
Lymphadenitidesc
Rheumatoid lymphadenopathies
Draining carcinomasd
Atypical lymphoid hyperplasias
Associated with SLEe
Associated with CVI'
74
28
57; 11/17
14
5
9
10/18; 22/6
21
60; 8/13
3
4
10
3
6/15; 16/5
25
58; 12/13
16
3
6
7/18; 11/14
12
60; 4/8
9
4
2
3
3
1
2
aMalignancy grades, according to the working formulation for clinical usage
(The non-Hodgkin's lymphoma pathologic classification project, 1989).
bAccording to the Ann Arbor System (Carbone et al, 1971). cTwo caused by
Epstein-Barr virus, one by human immunodeficiency virus, one by
Toxoplasma gondii. dTwo of breast and one of colon. The lymph node tissue
was tumour free. eSLE, systemic lupus erythematosus; 'CVI, common
variable immunodeficiency.
each of three sections (every third section within nine serial
sections) per sample were examined with a 144-intersection point
square reticulum (0.78 mm2) inserted in the eyepiece.
Care was taken to select microvessels, i.e. capillaries and small
venules, from all the stained vessels. They were identified as trans-
versally sectioned tubes with a single layer of endothelial cells,
either without or with a lumen (not exceeding 10 jm), and either
without or with a thin basement membrane. Each assessment was
agreed upon in turn. Microvessels showing reactivity with factor
VIII are ofboth blood and lymphatic origin and useful markers of
angiogenesis (Folkman et al, 1989). They were counted with a
planimetric point-count method (Elias and Hyde, 1983) with slight
modifications (Vacca et al, 1993), according to which only
microvessels transversally cut occupying the reticulum intersec-
tion points were counted. As the microvessel diameter was smaller
than the distance between adjacent intersection points, only one
transversally sectioned microvessel could occupy a given intersec-
tion point. Microvessels transversally sectioned outside the points
and those longitudinally or tangentially sectioned were omitted.
Therefore, it was sufficiently certain that a given microvessel was
counted only once, even in the presence of several of its section
planes. The method also makes allowances forthe inhomogeneous
distribution of microvessels in tissues (Elias and Hyde, 1983).
Indeed, in line with other (Kittas et al, 1985) and our own observa-
tions (Vacca et al, 1996), lymphadenopathies display very few
microvessels in follicles, and these mainly surround the mantle
zone and are scattered throughout the paracortical area and cords
of lymphocytes. No vessels are observed in the cords of histio-
cytes. In follicular subtypes oflow and intermediate grade, vessels
maintain a similar distribution, being very rare within follicles but
numerous in uninvolved tissue between as well as in areas repre-
senting either diffuse infiltration, or tissue shown as uninvolved
by immunohistochemistry. Low-grade small lymphocytic, diffuse
intermediate-grade and high-grade lymphomas show microvessels
irregularly scattered throughout the tumourtissue. As almostall of
each of three non-adjacent sections was analysed per sample, and
as microvessels transversally sectioned hit the intersection points
randomly, the method allowed objective counts in tissues of this
type. Means ± 1 standard deviation (s.d.) were determined foreach
section, sample and group ofsamples.
MC counts
MCs were highlighted in two sections adjacent to that stained for
microvessels with a 0.5% aqueous solution of toluidine blue
(Merk, Darmstadt, Germany). Cells were counted in 6-8 250x
fields, covering almost the whole section, inside the square retic-
ulum (0.25 mm2), and calculated as means ± 1 s.d. for each group
ofsamples.
Electron microscopy
Small pieces (approximately 1 mm3) of tissue were fixed in 3%
gluteraldehyde in 0.1 M phosphate-buffered saline (PBS) for 3 h,
washed in the same buffer for 12 h, post-fixed in 1% osmium
tetroxide, dehydrated in graded ethanols and embedded in Epon
812. Ultrathin sections were cut with a diamond knife on a LKB V
ultratome, stained with uranyl acetate followed by lead citrate and
examined in a 9A Zeiss electron microscope.
Table 2 Tissue density of microvessels and mast cells
Number Benign lymphadenopathies (12) B-cell non-Hodgkin's lymphomas
Low grade (28) Intermediate grade (21) High grade (25)
Microvessels (per 0.78 mm2) 4.4 ± 2.3 8.2 ± 3.1* 12.3 ± 4.1* 14.4 ± 3.9
Mast cells (per 0.25 mm2) 1.1 ±1.1 3.1 ± 2.1 * 6.4± 2.7* 8.2± 2.9
Number of samples between brackets. Results are expressed as means ± 1 standard deviation. *P< 0.05 compared with the preceding group (parametric
analysis of variance followed by Duncan's paired test).
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Figure 1 Adjacent sections of a benign lymphadenopathy and B-cell non-Hodgkin's lymphomas stained with factor VIII for microvessels (left, bar = 35gm) and
with toluidine blue for mast cells (right, bar = 15gum). (A) and (B), reactive lymphoid hyperplasia (Epstein-Barr virus lymphadenitis); (C) and (D), low grade
(small lymphocytic); (E) and (F), intermediate grade (follicular large cell); (G) and (H), high-grade (large cell, immunoblastic) lymphomas. Note the progressive
increase of microvessels and mast cells (some nests are arrowheaded) from A and B to G and H
RESULTS
Table 2 shows the counts of microvessels and MCs on adjacent
tissue sections ofbenign lymphadenopathies and B-NHL grouped
in WF malignancy grades. The microvessel counts were signifi-
cantly higher in low-grade B-NHL than in the lymphadenopathies,
still higher in intermediate-grade and higher again in the high-
grade tumours. In parallel, the MC counts were significantly
higher in low-grade B-NHL than in the benign tissues, and
increased progressively in the intermediate-grade and high-grade
tumours. These differences are also shown inFigure 1. The within-
group comparisons showed that both counts were always signifi-
cantly correlated (Figure 2).
MCs were generally scattered throughout the lymphomatous
tissue within the interstitial stroma where they rested near or
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Figure 2 Mast cell counts in comparison with microvessel counts in benign lymphadenopathies and in B-cell non-Hodgkin's lymphomas. Significance of the
regression analysis was calculated using Pearson's (r) test
around blood or lymphatic capillaries (Figure 3A and C). At the
ultrastructural level, MCs showed the typical features of the
connective tissue MCs, with their cytoplasmic matrix filled by
numerous electron-dense secretory granules (Figure 3B).
DISCUSSION
This paper shows that angiogenesis in benign lympadenopathies
and in B-NHL, measured as microvessel counts, is highly corre-
lated with the MC counts, and that both counts increase in step
with the increase in WF malignancy grades.
Both haematic and lymphatic endothelial cells of node tissues
have been shown to proliferate in vitro in response to angiogenic
cytokines, such as basic fibroblast growth factor (FGF-2) and
vascular endothelial growth factor (VEGF) (Pepper et al, 1994).
The peritumoral inflammatory infiltrate surrounding the newly
formed small blood and lymphatic vessels in the stroma ofB-NHL
consists of fibroblasts, MC and other leucocytes that may
contribute to induction of the angiogenic response by secreting
those factors (Folkman and Brem, 1992).
MCs are strikingly associated with angiogenesis, as found in
chronic inflammatory diseases, namely rheumatoid arthritis and
psoriasis, and in tumours, namely haemangiomas and carcinomas
(Meininger and Zetter, 1992; Norrby and Woolley, 1993; Qu et al,
1995). In tumours, MCs are recruited and activated via several
factors secreted by tumour cells: the c-kit receptor, or stem cell
factor (Poole and Zetter, 1983; Norrby and Wooley, 1993), as well
as FGF2, VEGF and platelet-derived endothelial cell growth
British Journal ofCancer (1998) 77(11), 1900-1906
5-
4-
3.
2.
a
0O o
a) E
0
.0
E
z
1-
-o .
r= 0.74
P < 0.01
I Il
12 14
a
0
a
a
E
0
.0
E
z
12 -
11 .
10.
9-
8-
7.-
6-
5-
4-
3-
2-
1-
0 _I
0 2 4 6 8 10
v * f.w n.
0 CancerResearch Campaign 19981904 D Ribatti etal
B
C
Figure 3 Histological (A) and ultrastructural (B) and (C) findings of a lymph node from the patient with the high-grade lymphoma reported in Figure 1.
(A) A mast cell with metachromatic cytoplasmatic granules is recognizable among tumour cells. (B) A mast cell with typical electron-dense round granules
and relatively few cytoplasmic organelles. (C) A mast cell (arrowhead) near a lymphatic capillary (double arrowhead) in the interstitial stroma. Original
magnifications: (A) bar = 2.5 mm; (B) bar = 0.7 mm; (C) bar = 2.1 gim
factor (PD-ECGF), which are operative at picomolar concentra-
tions (Gruber et al, 1995).
'[he fact that MCs contribute to the induction of tumour angio-
genesis stems from studies onMC-deficient mice, which give slow
angiogenesis, and its restoration after local reconstitution of MCs
(Starkey et al, 1988). MCs also contain heparin in secretory
granules. In vitro, heparin stimulates endothelial cell proliferation
and migration (Thorton et al, 1983; Alessandri et al, 1984),
whereas in vivo it has been found to stimulate (Ribatti et al, 1987;
Norrby and Sorbo, 1992; Norrby, 1993), inhibit (Jakobson and
Hahnenberger, 1991; Wilks et al, 1991; Norrby, 1993) or have no
effect (Castellot et al, 1982; Taylor and Folkman, 1982). However,
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these properties seem to be related to its molecular size and degree
of sulphation. The 22-kDa and 2.4-kDa heparin fractions display
stimulatory and inhibitory properties respectively (Norrby, 1993);
N-sulphate, but not 0-sulphate groups are necessary forthe release
of the extracellular matrix (heparan sulphate)-bound FGF-2 as
their whole replacement by acetyl or hexanoyl groups, despite the
normal 0-sulphate content, abolishes the FGF-2-releasing activity
(Ishai-Michaeli et al, 1992). This activity is because heparin acts
as a soluble form ofthe low-affinity FGF-2 receptor (Folkman and
Shing, 1992), which displaces FGF-2 in the biologically active
form, thus allowing its rapid interaction with endothelial cells
(Yayou et al, 1991).
Histamine, another MC-derived factor, also stimulates angio-
genesis (Sorbo et al, 1994), and tryptase, another MC mediator,
has been shown to be a potent angiogenic factor (Blair et al, 1997).
In addition, MCs produce a variety of multifunctional cytokines
and growth factors, such as transforming growth factorP (Roberts
et al, 1986), interleukins 6 and 8 (Motro et al, 1990; Norrby, 1996),
granulocyte macrophage-colony stimulating factor (Bussolino et
al, 1991), tumour necrosis factor x (Beil et al, 1994), FGF-2 (Qu et
al, 1995) and VEGF (Grutzkan et al, 1996), which may contribute
to angiogenesis in B-NHL.
In conclusion, our data suggest that an increasing number of
MCs may be recruited and activated by more malignant B-NHL
cells, and that angiogenesis associated with B-NHL may be medi-
ated by angiogenic factors contained in their secretory granules.
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